PD-1 PD-L1信号通路在实体瘤中的研究进展.pdfVIP

中国医药导报 年 月第 卷第 期 2015 4 12 10 ·综 述 · P 施敬瑶1 张海洋2 陈公琰 1▲ 1.哈尔滨医科大学附属肿瘤医院内一科，黑龙江哈尔滨 150081 ； 2. 哈尔滨医科大学附属肿瘤医院泌尿外科，黑龙江哈尔滨 150081 摘 近 信号通路因参 信 要 年来， 与肿瘤免疫逃逸而成为研究热点， 号通路的激活有助 [ ] PD-1/PD-L1 PD-1/PD-L1 于肿瘤细胞的免疫逃逸。 体内外实验证实，阻断该通路可增强机体内源性抗肿瘤免疫效应。 PD-1 及其配体PD- L1 的表达不仅与患者的临床分期及预后相关，还有可能成为临床生物标志物，而成为肿瘤免疫治疗的新靶点。 目前， 信号通路抑制剂已进入临床试验阶段，并且在治疗多种实体瘤中具有良好的疗效和安全性。 PD-1/PD-L1 [关键词] PD-1/PD-L1 信号通路；实体瘤；研究进展 中图分类号 R73 [文献标识码 A [文章编号 1673-7210（ 015 ） 4 （ ） 0047-04 [ ] ] ] 2 0 a - Research progress of PD-1/PD-L1 pathway in solid tumors SHI Jingyao1 ZHANG Haiyang2 CHEN Gongyan1▲ 1.The First Department of Internal Medicine, Cancer Hospital Affiliated to Harbin Medical University, Heilongjiang Province, Harbin 150081, China; 2.Department of Urology Surgery, Cancer Hospital Affiliated to Harbin Medical U- niversity, Heilongjiang Province, Harbin 150081, China [Abstract] In recent years, PD-1/PD-L1 pathway involves the mechanism of immune escape for tumor and become a hot pot. The activation of this pathway contribute to immune escape. Experiments confirm that blocking this pathway may enhance endogenous anti-tumor immune response. The express of PD-1 and its ligand PD-L1 not only reflect the clinical stage and prognosis, but also expect to become a clinical biomarker and then it will become a new target for cancer immunotherapy. Currently, drugs blocking PD-1 and PD-L1 have entered the stage of clinical trials,